{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:13Z","timestamp":1792131013200,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,1,22]],"date-time":"2015-01-22T00:00:00Z","timestamp":1421884800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00417-014-2925-7","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T22:40:36Z","timestamp":1421793636000},"page":"797-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin"],"prefix":"10.1007","volume":"253","author":[{"given":"Vahid","family":"Shayegannejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Shahzamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Dast Borhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzie","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mirmohammadsadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,22]]},"reference":[{"key":"2925_CR1","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1038\/sj.cdd.4401504","volume":"11","author":"MB S\u00e4ttler","year":"2004","unstructured":"S\u00e4ttler MB, Merkler D, Maier K et al (2004) Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 11:S181\u2013S192","journal-title":"Cell Death Differ"},{"key":"2925_CR2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/brain\/awh365","volume":"128","author":"R Diem","year":"2005","unstructured":"Diem R, S\u00e4ttler MB, Merkler D et al (2005) Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128:375\u2013385","journal-title":"Brain"},{"key":"2925_CR3","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/brain\/awm203","volume":"130","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Fischer B, Norra C et al (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130:2577\u20132588","journal-title":"Brain"},{"issue":"4","key":"2925_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s13760-014-0286-y","volume":"114","author":"F Najmi Varzaneh","year":"2014","unstructured":"Najmi Varzaneh F, Najmi Varzaneh F, Azimi AR, Rezaei N, Sahraian MA (2014) Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. Acta Neurol Belg 114(4):273\u2013278","journal-title":"Acta Neurol Belg"},{"key":"2925_CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.neucli.2013.09.004","volume":"43","author":"A Cr\u00e9ange","year":"2013","unstructured":"Cr\u00e9ange A, Lefaucheur JP, Balleyguier MO, Galact\u00e9ros F (2013) Iron depletion induced by bloodletting and followed by rhEPO administration as a therapeutic strategy in progressive multiple sclerosis: a pilot, open-label study with neurophysiological measurements. Neurophysiol Clin 43:303\u2013312","journal-title":"Neurophysiol Clin"},{"key":"2925_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1756285608098422","volume":"1","author":"C Bartels","year":"2008","unstructured":"Bartels C, Sp\u00e4te K, Krampe H, Ehrenreich H (2008) Recombinant Human Erythropoietin: novel strategies for neuroprotective\/neuro-regenerative treatment of multiple sclerosis. Ther Adv Neurol Disord 1:193\u2013206","journal-title":"Ther Adv Neurol Disord"},{"key":"2925_CR7","first-page":"151","volume":"17","author":"A Borhani-Haghighi","year":"2012","unstructured":"Borhani-Haghighi A, Ghodsi M, Razeghinejad MR et al (2012) Erythropoietin for acute multiple sclerosis in patients with optic neuritis as a first demyelination event. Neurosciences (Riyadh) 17:151\u2013155","journal-title":"Neurosciences (Riyadh)"},{"key":"2925_CR8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","volume":"72","author":"KW S\u00fchs","year":"2012","unstructured":"S\u00fchs KW, Hein K, S\u00e4ttler MB et al (2012) A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 72:199\u2013210","journal-title":"Ann Neurol"},{"key":"2925_CR9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jneuroim.2014.01.006","volume":"268","author":"H Chen","year":"2014","unstructured":"Chen H, Luo B, Yang X et al (2014) Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. J Neuroimmunol 268:64\u201370","journal-title":"J Neuroimmunol"},{"key":"2925_CR10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-62703-308-4_10","volume":"982","author":"I Cervellini","year":"2013","unstructured":"Cervellini I, Ghezzi P, Mengozzi M (2013) Therapeutic efficacy of erythropoietin in experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis. Methods Mol Biol 982:163\u2013173","journal-title":"Methods Mol Biol"},{"key":"2925_CR11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5115\/acb.2012.45.4.215","volume":"45","author":"T Shin","year":"2012","unstructured":"Shin T, Ahn M, Moon C, Kim S (2012) Erythropoietin and autoimmune neuroinflammation: lessons from experimental autoimmune encephalomyelitis and experimental autoimmune neuritis. Anat Cell Biol 45:215\u2013220","journal-title":"Anat Cell Biol"},{"key":"2925_CR12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2119\/molmed.2011.00457","volume":"18","author":"N Hagemeyer","year":"2012","unstructured":"Hagemeyer N, Boretius S, Ott C et al (2012) Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med 18:628\u2013635","journal-title":"Mol Med"},{"key":"2925_CR13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4103\/0253-7613.84955","volume":"43","author":"S Dasgupta","year":"2011","unstructured":"Dasgupta S, Mazumder B, Ramani YR, Bhattacharyya SP, Das MK (2011) Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis. Indian J Pharmacol 43:512\u2013515","journal-title":"Indian J Pharmacol"},{"key":"2925_CR14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2249.2010.04238.x","volume":"162","author":"SJ Chen","year":"2010","unstructured":"Chen SJ, Wang YL, Lo WT et al (2010) Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clin Exp Immunol 162:210\u2013223","journal-title":"Clin Exp Immunol"},{"key":"2925_CR15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","volume":"6","author":"AL Sir\u00e9n","year":"2009","unstructured":"Sir\u00e9n AL, Fasshauer T, Bartels C, Ehrenreich H (2009) Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6:108\u2013127","journal-title":"Neurotherapeutics"},{"key":"2925_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jneuroim.2005.10.016","volume":"172","author":"C Savino","year":"2006","unstructured":"Savino C, Pedotti R, Baggi F et al (2006) Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 172:27\u201337","journal-title":"J Neuroimmunol"},{"key":"2925_CR17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0006-8993(02)03239-0","volume":"952","author":"D Agnello","year":"2002","unstructured":"Agnello D, Bigini P, Villa P et al (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952:128\u2013134","journal-title":"Brain Res"},{"key":"2925_CR18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.20274","volume":"56","author":"W Li","year":"2004","unstructured":"Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P (2004) Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 56:767\u2013777","journal-title":"Ann Neurol"},{"key":"2925_CR19","first-page":"182","volume":"5","author":"MC Dooley","year":"2010","unstructured":"Dooley MC, Foroozan R (2010) Optic neuritis. J Ophthalmic Vis Res 5:182\u2013187","journal-title":"J Ophthalmic Vis Res"},{"key":"2925_CR20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581\u2013588","journal-title":"N Engl J Med"},{"key":"2925_CR21","first-page":"S36","volume":"72","author":"G Singbartl","year":"1994","unstructured":"Singbartl G (1994) Adverse events of erythropoietin in long-term and in acute\/short-term treatment. Clin Investig 72:S36\u2013S43","journal-title":"Clin Investig"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-014-2925-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2925-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:40:48Z","timestamp":1559058048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-014-2925-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,22]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["2925"],"URL":"https:\/\/doi.org\/10.1007\/s00417-014-2925-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,22]]}}}